IS8128A - Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða - Google Patents

Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða

Info

Publication number
IS8128A
IS8128A IS8128A IS8128A IS8128A IS 8128 A IS8128 A IS 8128A IS 8128 A IS8128 A IS 8128A IS 8128 A IS8128 A IS 8128A IS 8128 A IS8128 A IS 8128A
Authority
IS
Iceland
Prior art keywords
methyl
phenyl
carboxylic acid
paroxetine
trifluoro
Prior art date
Application number
IS8128A
Other languages
English (en)
Inventor
Melotto Sergio
Corsi Mauro
Carletti Renzo
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS8128A publication Critical patent/IS8128A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8128A 2003-04-17 2005-11-15 Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða IS8128A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments
PCT/EP2004/004126 WO2004091624A1 (en) 2003-04-17 2004-04-16 Combinations comprising paroxetine and 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety

Publications (1)

Publication Number Publication Date
IS8128A true IS8128A (is) 2005-11-15

Family

ID=9956996

Family Applications (2)

Application Number Title Priority Date Filing Date
IS8128A IS8128A (is) 2003-04-17 2005-11-15 Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða
IS8129A IS8129A (is) 2003-04-17 2005-11-15 Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS8129A IS8129A (is) 2003-04-17 2005-11-15 Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða

Country Status (18)

Country Link
US (4) US20060287325A1 (is)
EP (4) EP1653956A1 (is)
JP (4) JP2006523651A (is)
KR (2) KR20060003876A (is)
CN (2) CN1809355A (is)
AU (2) AU2004229179A1 (is)
BR (2) BRPI0409377A (is)
CA (2) CA2522311A1 (is)
CO (1) CO5700753A2 (is)
GB (1) GB0308968D0 (is)
IS (2) IS8128A (is)
MA (2) MA27731A1 (is)
MX (2) MXPA05011063A (is)
NO (2) NO20055368L (is)
PL (2) PL377857A1 (is)
RU (2) RU2005135649A (is)
WO (4) WO2004091615A1 (is)
ZA (2) ZA200508067B (is)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (en) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Stable dosage form of an antidepressant
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
WO2012175434A1 (en) * 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
AU735760B2 (en) * 1997-04-24 2001-07-12 Merck Sharp & Dohme Limited Use of a NK-1 receptor antagonist and an SSRI for treating obesity
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
CA2393672A1 (en) * 1999-12-17 2001-06-21 Schering Corporation Selective neurokinin antagonists
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
ES2291538T3 (es) * 2001-11-13 2008-03-01 Schering Corporation Antagonistas de nk1.
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1613325A1 (en) 2006-01-11
JP2006523650A (ja) 2006-10-19
AU2004229179A1 (en) 2004-10-28
WO2004091615A1 (en) 2004-10-28
ZA200508067B (en) 2007-02-28
US20060241124A1 (en) 2006-10-26
US20060217395A1 (en) 2006-09-28
IS8129A (is) 2005-11-15
WO2004091624A1 (en) 2004-10-28
PL377857A1 (pl) 2006-02-20
AU2004229181A1 (en) 2004-10-28
CN1809359A (zh) 2006-07-26
PL377858A1 (pl) 2006-02-20
BRPI0409379A (pt) 2006-04-25
CO5700753A2 (es) 2006-11-30
GB0308968D0 (en) 2003-05-28
KR20060003875A (ko) 2006-01-11
NO20055368L (no) 2005-11-14
CA2522311A1 (en) 2004-10-28
CN1809355A (zh) 2006-07-26
WO2004091617A1 (en) 2004-10-28
ZA200508068B (en) 2007-02-28
US20060241143A1 (en) 2006-10-26
EP1615641A1 (en) 2006-01-18
MA27731A1 (fr) 2006-01-02
BRPI0409377A (pt) 2006-04-25
MXPA05011063A (es) 2005-12-12
EP1653956A1 (en) 2006-05-10
JP2006523649A (ja) 2006-10-19
RU2005135649A (ru) 2006-03-20
JP2006523651A (ja) 2006-10-19
KR20060003876A (ko) 2006-01-11
WO2004091616A1 (en) 2004-10-28
MXPA05011064A (es) 2006-04-18
NO20055367L (no) 2005-11-14
RU2005135647A (ru) 2006-06-10
MA27730A1 (fr) 2006-01-02
EP1615642A1 (en) 2006-01-18
JP2006523652A (ja) 2006-10-19
US20060287325A1 (en) 2006-12-21
CA2522313A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
IS8128A (is) Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða
IS8214A (is) 3,5 tvísetin indasól enfasambönd, lyfjasamsetningar, og aðferðir til að miðla eða hindra frumufjölgun
IS7717A (is) Pýrídasínónafleiður sem PDF4-hemlar
DE602005011795D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
DK1537759T3 (da) Fremgangsmåde til at modvirke okklusionseffekter
EP2168578A3 (en) Thiazole based inhibitors of atp-utilizing enyzmes
ATE361279T1 (de) N-[phenyl(piperidin-2-yl)methyl]benzamidderivat , verfahren zu ihrer herstellung und ihre therapeutische anwendung
NO20050652L (no) Pyrrolidone derivater som maob inhibitorer
DE60317699D1 (de) Fermentationsverfahren und -zusammensetzungen
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
EP1911757B8 (en) Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors
DE60217363D1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen-abhängigen erkrankungen
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DK1484970T3 (da) Benzamider og sammensætninger omfattende benzamider til anvendelse som fungicider
IS7509A (is) Þíoxantínafleiður sem mergperoxídasatálmar
IL172542A0 (en) 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
IL176515A0 (en) 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
EP1572944A4 (en) METHOD AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF XBP-1
WO2004064832A3 (en) Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
AU2003286474A8 (en) Compositions, solutions, and methods used for transplantation
AU2003212850A1 (en) Methods and compositions for treating cardiovascular disease
ZA200606542B (en) 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
ATE373648T1 (de) Nf-kappab-inhibitoren
HK1063627A1 (en) New mandelic acid derivative and its use as thrombin inhibitors
DE60315255D1 (de) Zusammensetzung und verfahren zur bekämpfung von termiten